FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Relmada Therapeutics Stock Rises on Positive Drug Trial Results”
Relmada Therapeutics (NASDAQ: RLMD), Inc.climbed over 21% in premarket trading after the company announced top-line results of the human abuse potential study with REL-1017, company’s lead candidate in Phase 3 development for the treatment of major depressive disorder.
All three doses of REL-1017 showed a highly statistically significant difference in abuse potential vs. oxycodone and so far all tested parameters suggest a lack of any meaningful abuse potential for REL-1017 and are fully aligned with the 2019 DEA statement on methadone.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’ s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission.
For more information, please visit: Relmada Therapeutics
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.